Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
18.92
-0.04 (-0.21%)
At close: Apr 1, 2026, 4:00 PM EDT
18.49
-0.43 (-2.27%)
Pre-market: Apr 2, 2026, 5:44 AM EDT

Summit Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
---0.711.81
Revenue Growth (YoY)
----61.03%110.35%
Selling, General & Admin
-556.75-60.53-30.27-26.74-23.61
Research & Development
-537.67-135.77461.44-52-85.35
Other Operating Expenses
--0.31-1-5.95-20.97
Total Operating Expenses
-1,094-196.61430.18-84.69-129.93
Operating Income
1,094-226-609.65-72.09-86.19
Interest Expense
--8.69-16.46-4.4-
Other Non-Operating Income (Expense)
14.8413.3711.18-2.29-2.42
Total Non-Operating Income (Expense)
14.844.68-5.28-6.69-2.42
Pretax Income
1,109-221.32-614.93-78.78-88.6
Net Income
-1,080-221.32-614.93-78.78-88.6
Net Income to Common
-1,080-221.32-614.93-78.78-88.6
Shares Outstanding (Basic)
748719620193132
Shares Outstanding (Diluted)
748719620193132
Shares Change (YoY)
4.06%15.96%220.50%46.78%89.45%
EPS (Basic)
-1.44-0.31-0.99-0.41-0.67
EPS (Diluted)
-1.44-0.31-0.99-0.41-0.67
Free Cash Flow
-323.59-142.25-76.89-42.21-72.89
Free Cash Flow Per Share
-0.43-0.20-0.12-0.22-0.55
Gross Margin
---100.00%100.00%
Operating Margin
----10225.39%-4764.29%
Profit Margin
----11174.75%-4897.84%
FCF Margin
----5986.67%-4029.46%
EBITDA
1,095-225.91-607.6-70.83-83.73
EBITDA Margin
----10046.24%-4628.58%
EBIT
1,094-226-609.65-72.09-86.19
EBIT Margin
----10225.39%-4764.29%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q